Literature DB >> 15853594

Barnidipine: a new calcium channel blocker for hypertension treatment.

Chiau-Suong Liau1.   

Abstract

Although it is commonly agreed that all antihypertensive medications have similar efficacy, there are important differences related to safety, tolerability, patient adherence, cost effectiveness and effects on the prevention or retardation of associated disease progression. It is desirable for antihypertensives to have a long duration of action so that once-daily dosing is possible. In addition, antihypertensive medication must be able to be administered concomitantly with other drugs likely to be taken by the patients. This is particularly critical in the elderly population. Barnidipine, a novel, long-acting calcium antagonist, has met these challenges of modern pharmacotherapy. Its once-daily dosing, good tolerability and durable antihypertensive effect contribute to excellent patient adherence and make this drug a valuable addition to the antihypertensive formulary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15853594     DOI: 10.1586/14779072.3.2.207

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  7 in total

Review 1.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.

Authors:  Robert Lins; Yves Haerden; Caroline de Vries
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-03

3.  Effects of barnidipine on blood pressure and left ventricular diastolic function in patients with hypertension and metabolic syndrome: A 12-week, open-label noncomparison study.

Authors:  Fabio Angeli; Salvatore Repaci; Claudia Borgioni; Mariagrazia Sardone; Aurelio Scotti; Paolo Verdecchia
Journal:  Curr Ther Res Clin Exp       Date:  2008-06

4.  Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study.

Authors:  Giuseppe Rossetti; Samuele Pizzocri; Francesco Brasca; Marta Pozzi; Laura M Beltrami; Giovanni B Bolla; Roberta Famiani; Barbara Caimi; Stefano Omboni; Fabio Magrini; Stefano Carugo
Journal:  Curr Ther Res Clin Exp       Date:  2008-06

Review 5.  New generations of dihydropyridines for treatment of hypertension.

Authors:  Angela L Wang; Costantino Iadecola; Gang Wang
Journal:  J Geriatr Cardiol       Date:  2017-01       Impact factor: 3.327

6.  Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.

Authors:  Giuseppe Derosa; Amedeo Mugellini; Fabrizio Querci; Ivano Franzetti; Rosa Maria Pesce; Angela D'Angelo; Pamela Maffioli
Journal:  Sci Rep       Date:  2015-08-05       Impact factor: 4.379

Review 7.  How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension.

Authors:  Giuliano Tocci; Giovambattista Desideri; Elisa Roca; Calogero Calcullo; Massimo Crippa; Nicola De Luca; Giovanni Vincenzo Gaudio; Laura Maria Lonati; Leo Orselli; Angelo Scuteri; Vito Vulpis; Benedetto Acone; Augusto Zaninelli
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.